{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T02:58:24Z","timestamp":1774925904835,"version":"3.50.1"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T00:00:00Z","timestamp":1594252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100003323","name":"ANRS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To assess genotypic sensitivity scores (GSSs), plasma antiretroviral concentrations (PACs) and immunovirological outcomes at Week 96 (W96) in patients with persistent low-level viraemia (LLV).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>On 1 January 2017, we analysed data from patients on three-drug regimens with persistent LLV defined as at least two consecutive plasma viral loads (pVLs) between 21 and 200\u2009copies\/mL (including one pVL of \u226550\u2009copies\/mL), at the Piti\u00e9-Salp\u00eatri\u00e8re Hospital. Outcomes were: GSS, PACs and HIV-DNA load at study entry; and virological status and proportion of patients with resistance-associated mutations (RAMs) at W96.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Fifty-seven patients were included, with median age of 52.6\u2009years (IQR 45.2\u201357.9), last CD4 count of 658\u2009cells\/mm3 (IQR 462\u2013909) and total ART duration of 10.2\u2009years (IQR 5.7\u201315.2). LLV duration was 14.0\u2009months (IQR 5.5\u201322.3). GSS was 3 in 46\/57 (81%) patients and PACs were adequate in 53\/57 (93%) patients. Median total HIV-DNA was 2.65\u2009log10\u2009copies\/106\u2009cells (IQR 2.44\u20132.86). During follow-up, 26\/57 (46%) had experienced ART modifications. At W96, 38\/57 (67%) patients remained with LLV, 15\/60 (26%) had achieved confirmed pVL of &amp;lt;20\u2009copies\/mL and 4\/57 (7%) had virological failure. The four virological failures were due to three ART interruptions and one incomplete adherence (selection of Y181C RAM). No factors (patient characteristics at study entry, GSS, PACs, total HIV-DNA load and ART modification) were associated with W96 viral outcome, except for time from HIV diagnosis and the LLV duration at study entry.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>A substantial number of patients harbouring LLV had no resistance to ART and adequate PACs. Two-thirds of these patients remained with this LLV status.<\/jats:p><\/jats:sec>","DOI":"10.1093\/jac\/dkaa273","type":"journal-article","created":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T11:09:10Z","timestamp":1591700950000},"page":"2981-2985","source":"Crossref","is-referenced-by-count":18,"title":["Persistent low-level viraemia in antiretroviral treatment-experienced patients is not linked to viral resistance or inadequate drug concentrations"],"prefix":"10.1093","volume":"75","author":[{"given":"R","family":"Palich","sequence":"first","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Pierre Louis Epidemiology and Public Health Institute (iPLESP), AP-HP, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Department of Infectious Diseases, F-75013 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Wirden","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Pierre Louis Epidemiology and Public Health Institute (iPLESP), AP-HP, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Department of Virology, F-75013 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Peytavin","sequence":"additional","affiliation":[{"name":"Bichat University Hospital, AP-HP, Pharmacology and Toxicology Department, IAME, INSERM 1137, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4670-8288","authenticated-orcid":false,"given":"M -P","family":"L\u00ea","sequence":"additional","affiliation":[{"name":"Bichat University Hospital, AP-HP, Pharmacology and Toxicology Department, IAME, INSERM 1137, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Seang","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Pierre Louis Epidemiology and Public Health Institute (iPLESP), AP-HP, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Department of Infectious Diseases, F-75013 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Abdi","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Pierre Louis Epidemiology and Public Health Institute (iPLESP), AP-HP, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Department of Virology, F-75013 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Schneider","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Pierre Louis Epidemiology and Public Health Institute (iPLESP), AP-HP, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Department of Infectious Diseases, F-75013 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Tubiana","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Pierre Louis Epidemiology and Public Health Institute (iPLESP), AP-HP, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Department of Infectious Diseases, F-75013 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M -A","family":"Valantin","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Pierre Louis Epidemiology and Public Health Institute (iPLESP), AP-HP, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Department of Infectious Diseases, F-75013 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O","family":"Paccoud","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Pierre Louis Epidemiology and Public Health Institute (iPLESP), AP-HP, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Department of Infectious Diseases, F-75013 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Souli\u00e9","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Pierre Louis Epidemiology and Public Health Institute (iPLESP), AP-HP, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Department of Virology, F-75013 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Calvez","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Pierre Louis Epidemiology and Public Health Institute (iPLESP), AP-HP, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Department of Virology, F-75013 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Katlama","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Pierre Louis Epidemiology and Public Health Institute (iPLESP), AP-HP, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Department of Infectious Diseases, F-75013 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A -G","family":"Marcelin","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Pierre Louis Epidemiology and Public Health Institute (iPLESP), AP-HP, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Department of Virology, F-75013 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,7,9]]},"reference":[{"key":"2020101416144604800_dkaa273-B1","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(18)31311-4","article-title":"HIV","volume":"392","author":"Ghosn","year":"2018","journal-title":"Lancet"},{"key":"2020101416144604800_dkaa273-B2","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1128\/AAC.00076-14","article-title":"Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients","volume":"58","author":"Ryscavage","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2020101416144604800_dkaa273-B3","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1097\/QAD.0000000000000203","article-title":"HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure","volume":"28","author":"Swenson","year":"2014","journal-title":"AIDS"},{"key":"2020101416144604800_dkaa273-B4","doi-asserted-by":"crossref","first-page":"1004.e9","DOI":"10.1016\/j.cmi.2016.08.012","article-title":"A single untimed plasma drug concentration measurement during low-level HIV viremia predicts virologic failure","volume":"22","author":"Gonzalez-Serna","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"2020101416144604800_dkaa273-B5","doi-asserted-by":"crossref","first-page":"ofu119","DOI":"10.1093\/ofid\/ofu119","article-title":"Antiretroviral regimen and suboptimal medication adherence are associated with low-level human immunodeficiency virus viremia","volume":"2","author":"Konstantopoulos","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"2020101416144604800_dkaa273-B6","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/cid\/cit529","article-title":"Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation","volume":"57","author":"Laprise","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2020101416144604800_dkaa273-B7","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3851\/IMP3023","article-title":"Impact of low-level viraemia on virological failure in HIV-1-infected patients with stable antiretroviral treatment","volume":"21","author":"Navarro","year":"2016","journal-title":"Antivir Ther"},{"key":"2020101416144604800_dkaa273-B8","doi-asserted-by":"crossref","first-page":"e26320","DOI":"10.1371\/journal.pone.0026320","article-title":"Association of low level viremia with inflammation and mortality in HIV-infected adults","volume":"6","author":"Eastburn","year":"2011","journal-title":"PLoS One"},{"key":"2020101416144604800_dkaa273-B9","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/QAI.0b013e318258c651","article-title":"Episodes of HIV viremia and the risk of non-AIDS diseases in patients on suppressive antiretroviral therapy","volume":"60","author":"Zhang","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2020101416144604800_dkaa273-B10","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/jac\/dkq544","article-title":"Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia","volume":"66","author":"Wirden","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2020101416144604800_dkaa273-B11","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/bmc.865","article-title":"Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry","volume":"21","author":"Jung","year":"2007","journal-title":"Biomed Chromatogr BMC"},{"key":"2020101416144604800_dkaa273-B12","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/jmv.21390","article-title":"LTR real-time PCR for HIV-1 DNA quantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in HAART area (ANRS CO 01)","volume":"81","author":"Avettand-F\u00e8no\u00ebl","year":"2009","journal-title":"J Med Virol"},{"key":"2020101416144604800_dkaa273-B13","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1468-1293.2009.00719.x","article-title":"A large French prospective cohort of HIV-infected patients: the Nadis Cohort","volume":"10","author":"Pugliese","year":"2009","journal-title":"HIV Med"},{"key":"2020101416144604800_dkaa273-B14","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/infdis\/jir353","article-title":"Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy","volume":"204","author":"Taiwo","year":"2011","journal-title":"J Infect Dis"},{"key":"2020101416144604800_dkaa273-B15","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1097\/QAD.0000000000002306","article-title":"Low-level viremia and virologic failure in persons with HIV infection treated with antiretroviral therapy","volume":"33","author":"Fleming","year":"2019","journal-title":"AIDS"},{"key":"2020101416144604800_dkaa273-B16","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/cid\/ciy989","article-title":"Persistent low-level viremia predicts subsequent virologic failure: is it time to change the third 90?","volume":"69","author":"Esber","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2020101416144604800_dkaa273-B17","doi-asserted-by":"crossref","first-page":"ofy113","DOI":"10.1093\/ofid\/ofy113","article-title":"Impact of the M184V resistance mutation on virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals with suppressed HIV-1 RNA: a cohort study","volume":"5","author":"Gagliardini","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2020101416144604800_dkaa273-B18","doi-asserted-by":"crossref","first-page":"e0142923","DOI":"10.1371\/journal.pone.0142923","article-title":"Factors associated with low-level viraemia and virological failure: results from the Austrian HIV Cohort Study","volume":"10","author":"Leierer","year":"2015","journal-title":"PloS One"},{"key":"2020101416144604800_dkaa273-B19","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1093\/jac\/dkv099","article-title":"Low-level HIV-1 viraemia in patients on HAART: risk factors and management in clinical practice","volume":"70","author":"Wirden","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2020101416144604800_dkaa273-B20","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1093\/jac\/dkt484","article-title":"Markers associated with persisting low-level viraemia under antiretroviral therapy in HIV-1 infection","volume":"69","author":"Vancoillie","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2020101416144604800_dkaa273-B21","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/infdis\/jir208","article-title":"Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy","volume":"204","author":"Chun","year":"2011","journal-title":"J Infect Dis"},{"key":"2020101416144604800_dkaa273-B22","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1128\/CMR.00015-16","article-title":"Total HIV-1 DNA, a marker of viral reservoir dynamics with clinical implications","volume":"29","author":"Avettand-F\u00e8no\u00ebl","year":"2016","journal-title":"Clin Microbiol Rev"},{"key":"2020101416144604800_dkaa273-B23","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1016\/S2352-3018(15)00006-5","article-title":"CD4\/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study","volume":"2","author":"Mussini","year":"2015","journal-title":"Lancet HIV"},{"key":"2020101416144604800_dkaa273-B24","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1016\/S0140-6736(19)30418-0","article-title":"Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study","volume":"393","author":"Rodger","year":"2019","journal-title":"Lancet"},{"key":"2020101416144604800_dkaa273-B25","doi-asserted-by":"crossref","first-page":"9403","DOI":"10.1073\/pnas.0903107106","article-title":"Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy","volume":"106","author":"Dinoso","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020101416144604800_dkaa273-B26","doi-asserted-by":"crossref","first-page":"e1000321","DOI":"10.1371\/journal.pmed.1000321","article-title":"The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial","volume":"7","author":"Gandhi","year":"2010","journal-title":"PLoS Med"},{"key":"2020101416144604800_dkaa273-B27","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1086\/650749","article-title":"Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy","volume":"50","author":"McMahon","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2020101416144604800_dkaa273-B28","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1097\/QAD.0b013e3283177f49","article-title":"Switching to darunavir\/ritonavir achieves viral suppression in patients with persistent low replication on first-line lopinavir\/ritonavir","volume":"22","author":"Chaix","year":"2008","journal-title":"AIDS"},{"key":"2020101416144604800_dkaa273-B29","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3851\/IMP2815","article-title":"Virological outcome and management of persistent low-level viraemia in HIV-1-infected patients: 11 years of the Swiss HIV Cohort Study","volume":"20","author":"Boillat-Blanco","year":"2015","journal-title":"Antivir Ther"},{"key":"2020101416144604800_dkaa273-B30","doi-asserted-by":"crossref","first-page":"19785","DOI":"10.7448\/IAS.17.4.19785","article-title":"Antiretroviral therapy (ART) management of low-level viremia in Taiwan (ALLEVIATE)","volume":"17","author":"Cheng","year":"2014","journal-title":"J Int AIDS Soc"},{"key":"2020101416144604800_dkaa273-B31","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1128\/AAC.00409-12","article-title":"Maraviroc and other HIV-1 entry inhibitors exhibit a class-specific redistribution effect that results in increased extracellular viral load","volume":"56","author":"Kramer","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2020101416144604800_dkaa273-B32","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/00126334-200401010-00004","article-title":"Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication","volume":"35","author":"Ramratnam","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2020101416144604800_dkaa273-B33","doi-asserted-by":"crossref","first-page":"11212","DOI":"10.1128\/JVI.77.20.11212-11219.2003","article-title":"Productive infection maintains a dynamic steady-state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years","volume":"77","author":"Havlir","year":"2003","journal-title":"J Virol"},{"key":"2020101416144604800_dkaa273-B34","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1073\/pnas.1318249111","article-title":"Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues","volume":"111","author":"Fletcher","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020101416144604800_dkaa273-B35","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.3389\/fmicb.2019.02383","article-title":"Persistent HIV-1 viremia on antiretroviral therapy: measurement and mechanisms","volume":"10","author":"Jacobs","year":"2019","journal-title":"Front Microbiol"},{"key":"2020101416144604800_dkaa273-B36","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.virol.2017.07.010","article-title":"Longitudinal sequencing of HIV-1 infected patients with low-level viremia for years while on ART shows no indications for genetic evolution of the virus","volume":"510","author":"Vancoillie","year":"2017","journal-title":"Virology"},{"key":"2020101416144604800_dkaa273-B37","author":"Stam"},{"key":"2020101416144604800_dkaa273-B38","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1468-1293.2012.01002.x","article-title":"Comparison of resistance mutation patterns in historical plasma HIV RNA genotypes with those in current proviral HIV DNA genotypes among extensively treated patients with suppressed replication","volume":"13","author":"Delaugerre","year":"2012","journal-title":"HIV Med"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/10\/2981\/33885463\/dkaa273.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/10\/2981\/33885463\/dkaa273.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T07:27:28Z","timestamp":1723015648000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/75\/10\/2981\/5869070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,9]]},"references-count":38,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,7,9]]},"published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaa273","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,10]]},"published":{"date-parts":[[2020,7,9]]}}}